URAC Medicare Home Infusion Therapy Supplier Accreditation: From Gap Analysis to Accreditation Decision

Background

A regional specialty pharmacy with established URAC Specialty Pharmacy accreditation had been dispensing high-cost infusion medications to patients receiving therapy at home for several years. The organization's pharmacists maintained close relationships with infusion nurses contracted through a third-party nursing agency, but the pharmacy had not formally structured its operations to meet the Medicare home infusion therapy Conditions of Coverage. When CMS finalized the home infusion therapy benefit payment rules, the pharmacy's leadership recognized that billing Medicare Part B for infusion nursing visits would require MHITS accreditation — and that their existing Specialty Pharmacy accreditation, while valuable, did not confer Medicare HIT deemed status on its own.

The pharmacy engaged IHS to lead the accreditation process. Because the organization already held URAC Specialty Pharmacy accreditation, the IHS engagement was structured to leverage existing compliant infrastructure while identifying the MHITS-specific gaps that fell outside the Specialty Pharmacy standards.

Phase 1: Gap Analysis

IHS began with a structured gap analysis comparing the pharmacy's existing documented policies, procedures, clinical protocols, and quality management programs against URAC's MHITS standards. The analysis was conducted standard-by-standard across all MHITS domains — Practice Management, Consumer Protection and Empowerment, Complete Care Services, Practice Standards and Protocols, and Quality Management.

The gap analysis identified three categories of findings:

Phase 2: Policy and Protocol Development

Based on the gap analysis, IHS developed a prioritized remediation plan with ownership assignments, document templates, and completion milestones. The most consequential work in this phase was the development of a formal care coordination framework that defined:

• The roles and responsibilities of each member of the home infusion therapy team — pharmacist, contracted infusion nurse, prescriber, and patient/caregiver
• Required communication touchpoints at initiation, during therapy, at plan changes, and at discharge
• Documentation standards for each communication type, including who documents, where, and what elements are required
• Escalation protocols for adverse events, adherence failures, and clinical changes requiring prescriber notification
• A contractual framework governing the pharmacy's relationship with its contracted nursing agency that specified the nursing agency's obligations under the MHITS standards

IHS also developed revised patient and caregiver education protocols specific to home infusion therapy, including competency verification checklists for caregiver training, written education materials keyed to the infusion drugs the pharmacy most commonly dispensed, and a documentation process that created a retrievable record of education completion for each patient.

Phase 3: Operational Implementation and Staff Preparation

Policy development without operational implementation produces paper compliance — which URAC surveyors are trained to detect. IHS worked with the pharmacy's clinical and operations leadership over a six-week implementation period to:

• Train clinical and operational staff on the new care coordination framework, documentation requirements, and their individual responsibilities under the MHITS standards
• Implement the revised patient education documentation system in the pharmacy's dispensing workflow
• Establish a quality management data collection process to generate the performance metrics URAC requires be tracked and reviewed
• Brief the contracted nursing agency on the pharmacy's MHITS obligations and document the nursing agency's acknowledgment of its contractual compliance responsibilities

URAC surveyors conduct staff interviews across all organizational levels. IHS prepared clinical staff, operational staff, and supervisory leadership for the types of questions surveyors ask — both the standards-specific questions and the practice-based questions designed to determine whether policies reflect actual organizational behavior.

Phase 4: Mock Survey

Approximately three weeks before submitting the URAC application, IHS conducted a full mock survey. The mock survey followed URAC's survey methodology: document review against each standard, followed by staff interviews, followed by a written findings report. The mock survey identified two residual gaps:

1. The quality management program's performance metrics had been defined and data collection had begun, but the program had not yet completed a full improvement cycle. IHS worked with the pharmacy to document the cycle-in-progress in a way that demonstrated the program's operational structure even before the first formal review period was complete.
2. The nursing agency contract, while revised to address MHITS obligations, had not been executed in its updated form — the pharmacy was still operating under the prior contract. IHS accelerated the contract execution and confirmed the updated agreement was in place before the application was submitted.

Phase 5: Application and Survey

IHS assembled the application package — policy and procedure documentation, quality management program documentation, staff roster and competency evidence, the nursing agency contract, and supporting narrative responses — and coordinated the submission with the URAC application team. The application was submitted approximately four months after the engagement began.

The URAC survey was conducted on-site and via document review over two days. Surveyors interviewed pharmacy leadership, clinical pharmacists, operations staff, and the pharmacy's quality manager. IHS participated in the survey preparation call and was available for consultation during the survey period.

Outcome

URAC granted MHITS accreditation following the survey with no Request for Information (RFI) issued. The pharmacy received its accreditation decision approximately five months after the engagement began, and within six months of its initial engagement with IHS. The pharmacy subsequently enrolled as a Medicare home infusion therapy supplier and began billing Part B for infusion nursing services.